PMID: 15678666
Sheremet et al./PubMed/2005
Why It Matters
This caught my attention because intranasal delivery that reaches both brain and eye tissue is rare — most compounds don't cross the blood-brain barrier effectively. If this translates to humans, it could matter for conditions like glaucoma or optic nerve damage where current treatments are limited. But this is 2005 rat data using radioactive tracers to track distribution — interesting mechanism work, but we're a long way from knowing if it helps human vision.
Key Findings
- Tritium-labeled Semax reached both brain (cerebral cortex) and eye tissue after intranasal administration in rats
- The peptide maintained structural stability when exposed to electric fields during electrophoresis testing
- Semax showed electrophoretic mobility moving from positive to negative poles, requiring anode positioning for clinical electrophoresis delivery
- Study validated two potential delivery methods for optic nerve treatment: intranasal drops and electrophoresis
Read the Paper↗PMID: 15678666